PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 211 filers reported holding PACIRA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 0.59 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2022 | $46,000 | -82.8% | 788 | -77.4% | 0.00% | -77.8% |
Q1 2022 | $267,000 | +154.3% | 3,494 | +99.9% | 0.01% | +125.0% |
Q4 2021 | $105,000 | +2000.0% | 1,748 | +1800.0% | 0.00% | – |
Q3 2021 | $5,000 | -98.8% | 92 | -98.6% | 0.00% | -100.0% |
Q2 2021 | $402,000 | +688.2% | 6,622 | +681.8% | 0.01% | +550.0% |
Q4 2020 | $51,000 | -64.1% | 847 | -68.7% | 0.00% | -87.5% |
Q2 2020 | $142,000 | +202.1% | 2,706 | +118.4% | 0.02% | +14.3% |
Q3 2019 | $47,000 | +113.6% | 1,239 | +145.8% | 0.01% | +133.3% |
Q2 2019 | $22,000 | – | 504 | +4481.8% | 0.01% | – |
Q1 2019 | $0 | -100.0% | 11 | -87.8% | 0.00% | -100.0% |
Q2 2018 | $3,000 | -70.0% | 90 | -72.0% | 0.00% | -80.0% |
Q1 2018 | $10,000 | -33.3% | 321 | -0.3% | 0.01% | -54.5% |
Q4 2017 | $15,000 | +275.0% | 322 | +192.7% | 0.01% | +266.7% |
Q3 2017 | $4,000 | +300.0% | 110 | +423.8% | 0.00% | +200.0% |
Q2 2017 | $1,000 | -97.6% | 21 | -97.7% | 0.00% | -98.2% |
Q1 2017 | $42,000 | – | 931 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Tamarack Advisers, LP | 360,000 | $21,845,000 | 6.19% |
Gagnon Advisors, LLC | 213,217 | $12,938,000 | 4.92% |
GAGNON SECURITIES LLC | 499,333 | $30,300,000 | 4.30% |
Spyglass Capital Management LLC | 2,117,673 | $128,500,000 | 2.86% |
NEUMEIER POMA INVESTMENT COUNSEL LLC | 646,530 | $39,231,000 | 2.30% |
Paulson & Co. | 1,273,161 | $77,255,000 | 1.85% |
MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 212,112 | $12,871,000 | 1.44% |
Tygh Capital Management, Inc. | 152,332 | $9,244,000 | 1.26% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,147,000 | $69,600,000 | 1.24% |
Rock Springs Capital Management LP | 1,025,000 | $62,197,000 | 1.23% |